Shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) have earned an average rating of "Moderate Buy" from the thirteen research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.75.
Several equities research analysts have recently issued reports on ABCL shares. Wall Street Zen raised shares of AbCellera Biologics from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st. Piper Sandler boosted their price target on AbCellera Biologics from $12.00 to $20.00 and gave the company an "overweight" rating in a research note on Monday. JPMorgan Chase & Co. began coverage on shares of AbCellera Biologics in a research note on Tuesday, September 29th. They issued an "overweight" rating and a $17.00 price objective on the stock. Jefferies Financial Group reaffirmed a "buy" rating on shares of AbCellera Biologics in a report on Monday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AbCellera Biologics in a research note on Thursday, October 15th.
Check Out Our Latest Analysis on ABCL
AbCellera Biologics Trading Down 5.0%
ABCL opened at $10.47 on Friday. The company has a market cap of $3.42 billion, a P/E ratio of -21.81 and a beta of 1.59. The business's 50-day moving average price is $12.32 and its 200-day moving average price is $7.37. AbCellera Biologics has a 12 month low of $2.74 and a 12 month high of $15.02.
AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. The firm had revenue of $10.64 million for the quarter, compared to analysts' expectations of $8.42 million. AbCellera Biologics had a negative return on equity of 15.35% and a negative net margin of 218.54%. During the same period in the previous year, the firm posted ($0.19) earnings per share. Equities research analysts forecast that AbCellera Biologics will post -0.60 earnings per share for the current fiscal year.
Insider Buying and Selling
In other AbCellera Biologics news, major shareholder Holdings Ltd. Thermopylae acquired 60,565 shares of the company's stock in a transaction that occurred on Thursday, November 12th. The stock was acquired at an average cost of $11.54 per share, for a total transaction of $698,920.10. Following the transaction, the insider directly owned 56,194,662 shares in the company, valued at $648,486,399.48. This represents a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 28.40% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace LLP boosted its holdings in AbCellera Biologics by 370.9% in the 3rd quarter. Marshall Wace LLP now owns 8,958,273 shares of the company's stock valued at $130,701,000 after purchasing an additional 7,056,082 shares during the period. Bank of America Corp DE bought a new position in shares of AbCellera Biologics during the 2nd quarter valued at about $48,211,000. BlackRock Inc. purchased a new position in shares of AbCellera Biologics during the second quarter worth approximately $29,872,000. Goldman Sachs Group Inc. raised its position in AbCellera Biologics by 256.2% during the 3rd quarter. Goldman Sachs Group Inc. now owns 837,416 shares of the company's stock worth $12,218,000 after buying an additional 602,289 shares during the last quarter. Finally, Great Point Partners LLC purchased a new position in AbCellera Biologics in the 3rd quarter valued at about $8,754,000. 61.42% of the stock is owned by institutional investors.
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.